<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">8605732</journal-id><journal-id journal-id-type="pubmed-jr-id">2781</journal-id><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol. Immunother.</journal-id><journal-title-group><journal-title>Cancer immunology, immunotherapy : CII</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn></journal-meta><article-meta><article-id pub-id-type="pmid">25832000</article-id><article-id pub-id-type="pmc">4412651</article-id><article-id pub-id-type="doi">10.1007/s00262-015-1684-6</article-id><article-id pub-id-type="manuscript">EMS63119</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Crosstalk of carcinoembryonic antigen and transforming growth factor-&#x003b2; via their receptors: comparing human and canine cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jensen-Jarolim</surname><given-names>Erika</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fazekas</surname><given-names>Judit</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Singer</surname><given-names>Josef</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hofstetter</surname><given-names>Gerlinde</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Oida</surname><given-names>Kumiko</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Matsuda</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Akane</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Comparative Medicine, Comparative Immunology and Oncology, Messerli Research Institute of the University of Veterinary Medicine Vienna, c/o Institute of Pathophysiology and Allergy Research, AKH 4Q, Medical University Vienna and University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria
</aff><aff id="A2"><label>2</label>Comparative Animal Medicine, Division of Animal Life Science, Institute of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan
</aff><author-notes><corresp id="CR1">Erika Jensen-Jarolim, <email>erika.jensen-jarolim@meduniwien.ac.at</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>22</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>02</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>5</month><year>2015</year></pub-date><volume>64</volume><issue>5</issue><fpage>531</fpage><lpage>537</lpage><!--elocation-id from pubmed: 10.1007/s00262-015-1684-6--><permissions><copyright-statement>&#x000a9; The Author(s) 2015.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract><p id="P1">There is accumulating evidence that the transforming growth factor beta (TGF-&#x003b2;) and nuclear factor kappa-B (NF&#x003ba;B) pathways are tightly connected and play a key role in malignant transformation in cancer. Immune infiltration by regulatory T- and B-lymphocytes (Tregs, Bregs) has recently gained increased attention for being an important source of TGF-&#x003b2;. There is a plethora of studies examining the pro-tumorigenic functions of carcinoembryonic antigen (CEA), but its receptor CEAR is far less studied. So far, there is a single connecting report that TGF-&#x003b2; also may signal through CEAR. The crosstalk between cancer tissues is further complicated by the expression of CEAR and TGF-&#x003b2; receptors in stromal cells, and implications of TGF-&#x003b2; in epithelial&#x02013;mesenchymal transition. Furthermore, tumor-infiltrating Tregs and Bregs may directly instruct cancer cells by secreting TGF-&#x003b2; binding to their CEAR. Therefore, both TGF-&#x003b2; and CEA may act synergistically in breast cancer and cause disease progression, and NF&#x003ba;B could be a common crossing point between their signaling. CEAR, TGF-&#x003b2;1&#x02013;3, TGF-&#x003b2;-R types I&#x02013;III and NF&#x003ba;B class I and II molecules have an outstanding human&#x02013;canine sequence identity, and only a canine CEA homolog has not yet been identified. For these reasons, the dog may be a valid translational model patient for investigating the crosstalk of the interconnected CEA and TGF-&#x003b2; networks.</p></abstract><kwd-group><kwd>Carcinoembryonic antigen (CEA)</kwd><kwd>CEA-receptor (CEAR)</kwd><kwd>Transforming growth factor beta (TGF-&#x003b2;)</kwd><kwd>Cancer immunology</kwd><kwd>Regulatory</kwd><kwd>Nuclear factor kappa-B (NF&#x003ba;B)</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p id="P2">The strategy of comparative oncology is to find homologous molecules, homologous signaling cascades and homologous immune mechanisms to cure cancer in both humans and pets according to the &#x0201c;One Health&#x0201d; principle [<xref rid="R1" ref-type="bibr">1</xref>]. Similar to humans, dogs spontaneously develop malignancies with comparable incidence and prevalence and hence represent a natural model for human cancer. For instance, a Swedish study on 80,000 insured female dogs reported that, dependent on higher age and breed, up to 13 % of female dogs had at least one mammary tumor, with an overall-case fatality of 6 % [<xref rid="R2" ref-type="bibr">2</xref>]. In humans, females in more highly developed areas have a cumulative risk of 7.1 % of developing mammary cancer by the age of 75, with a mortality rate of 1.7 % [<xref rid="R3" ref-type="bibr">3</xref>]. Mammary carcinoma, among others, is thus a burden in both human and veterinary medicines.</p><p id="P3">The rationale for favouring this tumor entity for comparative studies derives from the fact that it is wise to have access to primary lesions for monitoring tumor progression by caliper measurements. This facilitates the clinical investigations and also takes into consideration that only few centers have access to imaging facilities. Often more than one mamilla are affected in canine cancer patients and may be compared side by side.</p><p id="P4">It can further be expected that results from comparative oncology studies, investigating naturally occurring cancers due to distinct risk factors in distinct breeds, have a higher translational potential than studies with genetically highly homologous mouse strains [<xref rid="R4" ref-type="bibr">4</xref>]. For example, the epidermal growth factor receptor (EGFR) family members EGFR (ErbB1) and human epidermal growth factor receptor 2 (HER-2 (ErbB2)) are molecules of outstanding homology between humans and dogs, and targeting of these molecules results in the same effects on signaling and cancer biology in both species [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>].</p><p id="P5">A more intricate situation was observed for the carcinoembryonic antigen [CEA, also termed carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)], which represents a classical soluble as well as membrane-expressed tumor marker in human clinical oncology. Serum levels of soluble human CEA correlate with disease progression [<xref rid="R7" ref-type="bibr">7</xref>], and its assessment is recommended in monitoring the treatment course of colorectal cancer in combination with other prognostic markers [<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>]. However, CEA molecules are structurally and evolutionarily diverse between humans and canines [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>]. A direct CEA homolog in dogs has not yet been defined and represents &#x0201c;a missing link&#x0201d; (<xref ref-type="table" rid="T1">Table 1</xref>). In contrast, overexpression of CEA in humans has been known for over 20 years to play an important role in metastasis and cell motility [<xref rid="R12" ref-type="bibr">12</xref>] by acting as a ligand for E- and L-selectins [<xref rid="R13" ref-type="bibr">13</xref>] and might have a signaling function probably by interacting with the Wnt pathway [<xref rid="R14" ref-type="bibr">14</xref>]. Furthermore, vaccination with an adeno-associated virus (AAV)&#x02013;CEA vector combined with Toll-like receptor-9 or Toll-like receptor-7 agonists in wild-type mice resulted in enhanced Th1-mediated immunity and protection from challenge with MC38 colon tumor cells expressing CEA, whereas the same CEA vaccines in CEA transgenic animals promoted tumor growth due to tolerance phenomena elicited by dendritic and myeloid cells [<xref rid="R15" ref-type="bibr">15</xref>]. Some CEA family members such as CEACAM6 may adhere to and inhibit tumor-infiltrating cytotoxic T cells [<xref rid="R16" ref-type="bibr">16</xref>]. CEACAM1, CEACAM5 and CEACAM6 may be released from epithelial tumors in microvesicles, whereas tumor endothelia only contain CEACAM1 which has a receptor function for other CEACAMs, influences T cell behavior [<xref rid="R17" ref-type="bibr">17</xref>] and regulates the tumor matrix and microvascularization [<xref rid="R18" ref-type="bibr">18</xref>]. Hence, CEA may affect the tumor and its stroma at the same time [<xref rid="R19" ref-type="bibr">19</xref>].</p></sec><sec id="S2"><title>CEAR binds TGF-&#x003b2;, a cytokine involved in tolerance induction toward malignant tissue</title><p id="P6">The scientific history of the carcinoembryonic antigen receptor (CEAR) is much more recent. Interestingly, CEAR showed an outstanding sequence identity of 99 % between the human and canine species [<xref rid="R20" ref-type="bibr">20</xref>] (<xref ref-type="table" rid="T1">Table 1</xref>). The great CEA-receptor homology of humans and dogs on the one hand and the lack of a precise canine CEA equivalent on the other hand are discrepancies and indicate that there could be an alternative ligand. The CEAR was originally described in Kupffer cells and identified as the heterogeneous nuclear ribonucleoprotein M4 (hnRNP M4) [<xref rid="R21" ref-type="bibr">21</xref>]. Regarding oncology, it was later also found on colon cancer cells [<xref rid="R22" ref-type="bibr">22</xref>]. Moreover, its expression was subsequently also detected in mice in the entire gastrointestinal tract including liver and pancreas [<xref rid="R23" ref-type="bibr">23</xref>]. CEAR expression has been connected to inflammation in the liver [<xref rid="R24" ref-type="bibr">24</xref>]. In Kupffer cells, a full-length hnRNP M4 (CEARL) and a truncated form (CEARS), generated by alternative splicing, were described [<xref rid="R14" ref-type="bibr">14</xref>]. The minimal structural element of human CEACAM5 interacting with hnRNP M4/CEAR was reduced to a peptide of eight amino acids [<xref rid="R25" ref-type="bibr">25</xref>].</p><p id="P7">Surprisingly, a recent study has shown that CEA not only signals via its specific receptor, CEAR, but can also bind to the receptor of the important immunomodulatory cytokine transforming growth factor beta (TGF-&#x003b2;, <xref ref-type="fig" rid="F1">Fig. 1</xref>) [<xref rid="R26" ref-type="bibr">26</xref>].</p></sec><sec id="S3"><title>TGF-&#x003b2; sources and its function in the tumor</title><p id="P8">Three high-affinity membrane-bound receptors for TGF-&#x003b2; are known so far: type I, type II and type III. The classical TGF-&#x003b2; signaling, however, occurs via the heterotetrameric complex of 2 TGF-&#x003b2;-receptor (TGF-&#x003b2;-R) type I and 2 TGF-&#x003b2;-receptor type II transmembrane receptors with serine/threonine kinase activity [<xref rid="R27" ref-type="bibr">27</xref>-<xref rid="R29" ref-type="bibr">29</xref>]. In the tumor microenvironment, TGF-&#x003b2; is most typically derived from human and canine Foxp3<sup>+</sup> regulatory T cells (Tregs). It is well known that Tregs can thereby critically dampen anti-tumor immunity and tolerize cytotoxic T cells [<xref rid="R30" ref-type="bibr">30</xref>-<xref rid="R34" ref-type="bibr">34</xref>]. More recently, intratumoral regulatory B cells (Bregs) have gained attention in human oncology [<xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R36" ref-type="bibr">36</xref>]. According to Olkhanud et al. [<xref rid="R37" ref-type="bibr">37</xref>], tumor-evoked Bregs should phenotypically resemble activated mature B2 cells (CD19<sup>+</sup> CD25<sup>hi</sup> CD69<sup>hi</sup>). Lindner et al. [<xref rid="R36" ref-type="bibr">36</xref>] reported that intratumoral Bregs also express granzyme-B (stimulated by IL-21 from Tregs) and a signature of CD19<sup>+</sup>CD38<sup>+</sup>CD1d<sup>+</sup>IgM<sup>+</sup>CD147<sup>+</sup>, as well as including IL-10, CD25 and indoleamine-2,3-dioxygenase. This population seems interesting as a source of TGF-&#x003b2; and for their capacity to suppress intratumoral CD8<sup>+</sup> and CD4<sup>+</sup> effector T cells. Bregs can even convert na&#x000ef;ve CD4<sup>+</sup>CD25<sup>&#x02212;</sup> T cells to Foxp3<sup>+</sup> Tregs [<xref rid="R37" ref-type="bibr">37</xref>]. TGF-&#x003b2;, however, may also be derived from tumor stroma cells [<xref rid="R19" ref-type="bibr">19</xref>, <xref rid="R38" ref-type="bibr">38</xref>], where it shapes the microenvironment by interacting with growth factors (epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF) [<xref rid="R39" ref-type="bibr">39</xref>]), cytokines or chemokines, crosstalking to fibroblasts [<xref rid="R40" ref-type="bibr">40</xref>] and supporting the enrichment of endothelial cells, which again shape the extracellular matrix [<xref rid="R41" ref-type="bibr">41</xref>]. TGF-&#x003b2; promotes the loss of epithelial markers such as E-cadherin and the accumulation of the mesenchymal marker vimentin in the process of epithelial&#x02013;mesenchymal transition (EMT) [<xref rid="R42" ref-type="bibr">42</xref>]. Importantly, in this case tumor stem cells themselves show an enrichment of mesenchymal markers and are a source of TGF-&#x003b2;. Most studies on EMT are done in mouse or human cancer models [<xref rid="R43" ref-type="bibr">43</xref>], but there are reports that EMT transition can be achieved by TGF-&#x003b2; in (normal) Madin&#x02013;Darby canine kidney (MDCK) cells [<xref rid="R44" ref-type="bibr">44</xref>].</p><p id="P9">Physiologically, TGF-&#x003b2; acts as a tumor suppressor, negatively regulating cellular proliferation, but this is changed in the cancer microenvironment toward a tumor promoter function, where it mediates proliferation, migration, invasion, EMT and metastasis, associated with high miR-181a expression, and altogether termed the TGF-&#x003b2;-paradox [<xref rid="R45" ref-type="bibr">45</xref>]. In this context, it is important to note that canines are much closer to the human species than murine animal models. The appearance of Tregs also negatively correlates with prognosis in dog cancer patients [<xref rid="R46" ref-type="bibr">46</xref>].</p><p id="P10">For instance, naive CD4<sup>+</sup>CD25<sup>&#x02212;</sup>Foxp3<sup>&#x02212;</sup> T cells can be converted to Foxp3<sup>+</sup> Tregs when adoptively transferred into Rag<sup>&#x02212;/&#x02212;</sup> mice only in the presence of TGF-&#x003b2;-positive tumors [<xref rid="R47" ref-type="bibr">47</xref>]. Thus, the intratumoral milieu amplifies the cellular sources for even more immunosuppressive cytokines. It has been recently shown that elevated levels of TGF-&#x003b2; and IL-6 in the tumor microenvironment support Th17 cells and that the resulting inflammation was supporting the clinical development and progression of gastric cancer [<xref rid="R48" ref-type="bibr">48</xref>]. Although Li et al. have shown that CEA binds to TGF-&#x003b2;-R [<xref rid="R26" ref-type="bibr">26</xref>], it has not yet been investigated whether the reverse is true, and TGF-&#x003b2; (besides acting via its own TGF-&#x003b2;-R) may crosstalk via CEAR, thereby imitating the tumor-progressive properties of CEA. CEA modulates effector&#x02013;target interaction by binding to lymphocytes [<xref rid="R49" ref-type="bibr">49</xref>]. Only CEACAM1 expression was previously described in T cells [<xref rid="R50" ref-type="bibr">50</xref>], whereas the expression of CEACAM5 on T cells was excluded. Regarding this, we are not aware of investigations on the expression of CEAR on T- or B-lymphocytes.</p></sec><sec id="S4"><title>TGF-&#x003b2; signaling</title><p id="P11">In contrast to CEAR, the cellular signaling function of which has to the best of our knowledge not yet been reported, the signaling cascade for the TGF-&#x003b2;-R is well known. The nuclear factor kappa-B (NF&#x003ba;B) is a key master regulator in growth and survival [<xref rid="R51" ref-type="bibr">51</xref>, <xref rid="R52" ref-type="bibr">52</xref>]. In normal cells, TGF-&#x003b2; leads to growth inhibition; in short: TGF-&#x003b2; binds to TGF-&#x003b2;-RII, activating TGF-&#x003b2;-RI and then phosphorylating the SMA and MAD homologs SMAD2 and SMAD3, which associate with SMAD4 and together translocate to the nucleus for transcription of genes. All of this is inhibited by SMAD7 [<xref rid="R53" ref-type="bibr">53</xref>]. Interestingly, the TGF-&#x003b2;-R-initiated SMAD pathway was shown to target CEACAM5 (and CEACAM6) genes leading to CEA secretion as a mechanism for proliferation in gastric cancer cells [<xref rid="R54" ref-type="bibr">54</xref>]. It will be interesting in the future to investigate whether a synergistic crosstalk between the CEA and TGF-&#x003b2; signaling cascades in cancer cells exists.</p><p id="P12">In human head and neck squamous cell carcinoma cell lines, Freudlsperger et al. [<xref rid="R53" ref-type="bibr">53</xref>] could further demonstrate that TGF-&#x003b2; signaling resulted in a sequential phosphorylation of the transforming growth factor-activated kinase-1 (TAK1), inhibitor of nuclear factor kappa-B kinase (IKK), inhibitor of kappa-B subunit alpha (I&#x003ba;B&#x003b1;) and the v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA); however, the crosstalk to CEA was not addressed in this study. Nor did this study address the consecutive activation of TAK1/mitogen-activated protein kinase kinase (MEK)/protein kinase B (AKT)/NF&#x003ba;B and SMAD pathways upon TGF-&#x003b2; stimulation as Gingery et al. [<xref rid="R55" ref-type="bibr">55</xref>] did in osteoclasts.</p><p id="P13">In human cancers, mutations in the TGF-&#x003b2; pathways (e.g., TGF-&#x003b2;-RII or SMAD4) are frequently observed [<xref rid="R56" ref-type="bibr">56</xref>]. A recent study has indicated that, although most tested colorectal cancer cells displayed an inactivated TGF-&#x003b2; signaling pathway, they actively secreted TGF-&#x003b2; acting on stromal cells and were thus driving metastasis [<xref rid="R57" ref-type="bibr">57</xref>]. In other cancer cell types, TGF-&#x003b2; signaling is intact, but aberrant NF&#x003ba;B activation and NF&#x003ba;B/RelA stimulate proliferation. In this respect, it should be emphasized that NF&#x003ba;B is constitutively activated in a number of hematologic and solid tumors and is one of the major transcription factors associated with cancer progression, inhibition of apoptosis, limitless replicative potential, tissue invasion and metastasis [<xref rid="R58" ref-type="bibr">58</xref>].</p><p id="P14">The TGF-&#x003b2;-R and NF&#x003ba;B pathways are connected via the TAK-1, which (independently, but parallel to SMAD activation) by phosphorylating IKK can directly stimulate the nuclear factor-&#x003ba;B (NF&#x003ba;B) pathway [<xref rid="R55" ref-type="bibr">55</xref>]. It is tempting to speculate that CEA may induce similar signals by interacting with TGF-&#x003b2;-R [<xref rid="R26" ref-type="bibr">26</xref>]. TAK1 was expressed in head and neck cancers, where nuclear activation of RelA of the NF&#x003ba;B family also took place. TGF-&#x003b2; induced sequential phosphorylation of several targets including TAK1, IKK, I&#x003ba;B&#x003b1; and RelA; additionally, TAK1 again enhanced TGF-&#x003b2; induced NF&#x003ba;B activation [<xref rid="R53" ref-type="bibr">53</xref>]. In human neutrophils, a constitutive association of TAK1 and inhibitor of kappa-B (I&#x003ba;B) was recently reported, indicating a close association of these pathways in inflammatory cells [<xref rid="R59" ref-type="bibr">59</xref>]. Neil et al. could show that the TAK1-binding protein 1 (TAB 1) forms complexes with I&#x003ba;B kinase b (IKKb) resulting in stimulation of the TAK1:IKKb:RelA pathway. The authors concluded that this axis, including the NF&#x003ba;B elements, is pivotal in the oncogenic transformation of breast cancer [<xref rid="R60" ref-type="bibr">60</xref>]. The fact that NF&#x003ba;B plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells may additionally complicate the situation [<xref rid="R61" ref-type="bibr">61</xref>].</p></sec><sec sec-type="conclusions" id="S5"><title>Conclusion</title><p id="P15">Generally, the dog represents an optimal model organism to study cancer biology in a comparative setting, as many genes represent a great degree of homology to their human counterparts [<xref rid="R62" ref-type="bibr">62</xref>]. Even with respect to noncoding RNAs, the significance of similarities between human and dog has recently been acknowledged [<xref rid="R63" ref-type="bibr">63</xref>]. Furthermore, the intriguing amino acid homogeneity among human and canine CEAR, TGF-&#x003b2; and TGF-&#x003b2;-R isoforms, NF&#x003ba;B and RelA are given in <xref ref-type="table" rid="T1">Table 1</xref>, indicating again an advantage of the dog patient in comparative oncology.</p><p id="P16">We propose that understanding of the crosstalk between CEA and TGF-&#x003b2; signaling toward NF&#x003ba;B as a key cancer regulator, as well as understanding of the Treg and Breg action in tumor tissue, should be extended, possibly with prognostic value. The dog may be a relevant translational model to study these interactions, in line with the comparative oncology strategy [<xref rid="R64" ref-type="bibr">64</xref>]. In the future, novel drugs may target the Achilles heel of both obviously interconnected networks.</p></sec></body><back><ack id="S6"><title>Acknowledgments</title><p>The authors were supported by Project P23398-B11 of the Austrian Science Fund (FWF), Judit Fazekas by the Cell Communication in Health and Disease (CCHD) PhD Program W1205-B09 of the Austrian Science Fund (FWF). We would like to thank Mrs. Amelia Wein for proofreading the manuscript.</p></ack><fn-group><fn id="FN1"><p id="P17"><bold>Conflict of interest</bold> The authors declare that they have no conflict of interest pertaining to the contents of this article.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term>AAV</term><def><p>Adeno-associated virus</p></def></def-item><def-item><term>Akt</term><def><p>Protein kinase B</p></def></def-item><def-item><term>Breg</term><def><p>Regulatory B-lymphocyte</p></def></def-item><def-item><term>CEA</term><def><p>Carcinoembryonic antigen (CEACAM5)</p></def></def-item><def-item><term>CEACAM</term><def><p>Carcinoembryonic antigen-related cell adhesion molecule</p></def></def-item><def-item><term>CEAR</term><def><p>Carcinoembryonic antigen receptor</p></def></def-item><def-item><term>CEARL</term><def><p>Carcinoembryonic antigen receptor, long isoform</p></def></def-item><def-item><term>CEARS</term><def><p>Carcinoembryonic antigen receptor, short isoform</p></def></def-item><def-item><term>EGF</term><def><p>Epidermal growth factor</p></def></def-item><def-item><term>EGFR</term><def><p>Epidermal growth factor receptor (ErbB1)</p></def></def-item><def-item><term>EMT</term><def><p>Epithelial-to-mesenchymal transition</p></def></def-item><def-item><term>FGF</term><def><p>Fibroblast growth factor</p></def></def-item><def-item><term>HER-2</term><def><p>Human epidermal growth factor receptor 2 (ErbB2)</p></def></def-item><def-item><term>HGF</term><def><p>Hepatocyte growth factor</p></def></def-item><def-item><term>hnRNP M4</term><def><p>Heterogeneous nuclear ribonucleoprotein M4 (CEAR)</p></def></def-item><def-item><term>IGFs</term><def><p>Insulin-like growth factors</p></def></def-item><def-item><term>IKK</term><def><p>Inhibitor of nuclear factor kappa-B kinase</p></def></def-item><def-item><term>IKKb</term><def><p>Inhibitor of nuclear factor kappa-B kinase subunit beta</p></def></def-item><def-item><term>I&#x003ba;B</term><def><p>Inhibitor of kappa-B</p></def></def-item><def-item><term>I&#x003ba;B&#x003b1;</term><def><p>Inhibitor of kappa-B subunit alpha</p></def></def-item><def-item><term>MDCK</term><def><p>Madin&#x02013;Darby canine kidney cell line</p></def></def-item><def-item><term>MEK</term><def><p>Mitogen-activated protein kinase kinase</p></def></def-item><def-item><term>NF&#x003ba;B</term><def><p>Nuclear factor kappa-B</p></def></def-item><def-item><term>PDGF</term><def><p>Platelet-derived growth factor</p></def></def-item><def-item><term>RelA</term><def><p>v-Rel avian reticuloendotheliosis viral oncogene homolog A</p></def></def-item><def-item><term>SMAD</term><def><p>SMA and MAD homolog</p></def></def-item><def-item><term>TAB1</term><def><p>TAK1-binding protein 1</p></def></def-item><def-item><term>TAK1</term><def><p>Transforming growth factor-activated kinase-1</p></def></def-item><def-item><term>TGF-&#x003b2;</term><def><p>Transforming growth factor beta</p></def></def-item><def-item><term>TGF-&#x003b2;-R</term><def><p>Transforming growth factor beta receptor</p></def></def-item><def-item><term>Treg</term><def><p>Regulatory T-lymphocyte</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>The American Veterinary Medical Association</collab><collab>One health initiative task force</collab></person-group><date-in-citation>Accessed Sept 27 2013</date-in-citation><source>One health: a new professional imperative</source><comment><ext-link ext-link-type="uri" xlink:href="http://https://www.avma.org/KB/Resources/Reports/Documents/one-health_final.pdf">https://www.avma.org/KB/Resources/Reports/Documents/one-health_final.pdf</ext-link></comment></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egenvall</surname><given-names>A</given-names></name><name><surname>Bonnett</surname><given-names>BN</given-names></name><name><surname>Ohagen</surname><given-names>P</given-names></name><name><surname>Olson</surname><given-names>P</given-names></name><name><surname>Hedhammar</surname><given-names>A</given-names></name><name><surname>von Euler</surname><given-names>H</given-names></name></person-group><article-title>Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002</article-title><source>Prev Vet Med</source><year>2005</year><volume>69</volume><fpage>109</fpage><lpage>127</lpage><comment>doi:10.1016/j.prevetmed.2005.01.014</comment><pub-id pub-id-type="pmid">15899300</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><year>2011</year><volume>61</volume><fpage>69</fpage><lpage>90</lpage><comment>doi:10.3322/caac.20107</comment><pub-id pub-id-type="pmid">21296855</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>SH</given-names></name><name><surname>Garner</surname><given-names>JP</given-names></name><name><surname>Auer</surname><given-names>C</given-names></name><name><surname>Kunert</surname><given-names>J</given-names></name><name><surname>Wurbel</surname><given-names>H</given-names></name></person-group><article-title>Systematic variation improves reproducibility of animal experiments</article-title><source>Nat Methods</source><year>2010</year><volume>7</volume><fpage>167</fpage><lpage>168</lpage><comment>doi:10.1038/nmeth0310-167</comment><pub-id pub-id-type="pmid">20195246</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Weichselbaumer</surname><given-names>M</given-names></name><name><surname>Stockner</surname><given-names>T</given-names></name><etal/></person-group><article-title>Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting</article-title><source>Mol Immunol</source><year>2012</year><volume>50</volume><fpage>200</fpage><lpage>209</lpage><comment>doi:10.1016/j.molimm.2012.01.002</comment><pub-id pub-id-type="pmid">22424313</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Fazekas</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients</article-title><source>Mol Cancer Ther</source><year>2014</year><volume>13</volume><fpage>1777</fpage><lpage>1790</lpage><comment>doi:10.1158/1535-7163.MCT-13-0288</comment><pub-id pub-id-type="pmid">24755200</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwanicki-Caron</surname><given-names>I</given-names></name><name><surname>Di Fiore</surname><given-names>F</given-names></name><name><surname>Roque</surname><given-names>I</given-names></name><etal/></person-group><article-title>Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>3681</fpage><lpage>3686</lpage><comment>doi:10.1200/jco.2007.15.0904</comment><pub-id pub-id-type="pmid">18669452</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bast</surname><given-names>RC</given-names></name><name><surname>Ravdin</surname><given-names>P</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name><etal/></person-group><article-title>2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the american society of clinical oncology*</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>1865</fpage><lpage>1878</lpage><pub-id pub-id-type="pmid">11251019</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogoshi</surname><given-names>K</given-names></name><name><surname>Miyaji</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Kondoh</surname><given-names>Y</given-names></name><name><surname>Makuuchi</surname><given-names>H</given-names></name><name><surname>Tajima</surname><given-names>T</given-names></name></person-group><article-title>Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute-phase reactants</article-title><source>Cancer Immunol Immunother: CII</source><year>1998</year><volume>46</volume><fpage>14</fpage><lpage>20</lpage></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zebhauser</surname><given-names>R</given-names></name><name><surname>Kammerer</surname><given-names>R</given-names></name><name><surname>Eisenried</surname><given-names>A</given-names></name><name><surname>McLellan</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>T</given-names></name><name><surname>Zimmermann</surname><given-names>W</given-names></name></person-group><article-title>Identification of a novel group of evolutionarily conserved members within the rapidly diverging murine Cea family</article-title><source>Genomics</source><year>2005</year><volume>86</volume><fpage>566</fpage><lpage>580</lpage><comment>doi:10.1016/j.ygeno.2005.07.008</comment><pub-id pub-id-type="pmid">16139472</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kammerer</surname><given-names>R</given-names></name><name><surname>Popp</surname><given-names>T</given-names></name><name><surname>Hartle</surname><given-names>S</given-names></name><name><surname>Singer</surname><given-names>BB</given-names></name><name><surname>Zimmermann</surname><given-names>W</given-names></name></person-group><article-title>Species-specific evolution of immune receptor tyrosine based activation motif-containing CEACAM1-related immune receptors in the dog</article-title><source>BMC Evol Biol</source><year>2007</year><volume>7</volume><fpage>196</fpage><comment>doi:10.1186/1471-2148-7-196</comment><pub-id pub-id-type="pmid">17945019</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hostetter</surname><given-names>RB</given-names></name><name><surname>Augustus</surname><given-names>LB</given-names></name><name><surname>Mankarious</surname><given-names>R</given-names></name><name><surname>Chi</surname><given-names>K</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Toth</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Jessup</surname><given-names>JM</given-names></name></person-group><article-title>Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis</article-title><source>J Natl Cancer Inst</source><year>1990</year><volume>82</volume><fpage>380</fpage><lpage>385</lpage><comment>doi:10.1093/jnci/82.5.380</comment><pub-id pub-id-type="pmid">2304087</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>SN</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Schnaar</surname><given-names>RL</given-names></name><name><surname>Alves</surname><given-names>CS</given-names></name><name><surname>Konstantopoulos</surname><given-names>K</given-names></name></person-group><article-title>Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>15647</fpage><lpage>15655</lpage><comment>doi:10.1074/jbc.M800543200</comment><pub-id pub-id-type="pmid">18375392</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajenova</surname><given-names>O</given-names></name><name><surname>Chaika</surname><given-names>N</given-names></name><name><surname>Tolkunova</surname><given-names>E</given-names></name><name><surname>Davydov-Sinitsyn</surname><given-names>A</given-names></name><name><surname>Gapon</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S</given-names></name></person-group><article-title>Carcinoembryonic antigen promotes colorectal cancer progression by targeting adherens junction complexes</article-title><source>Exp Cell Res</source><year>2014</year><volume>324</volume><fpage>115</fpage><lpage>123</lpage><comment>doi:10.1016/j.yexcr.2014.04.007</comment><pub-id pub-id-type="pmid">24726916</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triozzi</surname><given-names>PL</given-names></name><name><surname>Aldrich</surname><given-names>W</given-names></name><name><surname>Ponnazhagan</surname><given-names>S</given-names></name></person-group><article-title>Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists</article-title><source>Cancer Gene Ther</source><year>2011</year><volume>18</volume><fpage>850</fpage><lpage>858</lpage><comment>doi:10.1038/cgt.2011.54</comment><pub-id pub-id-type="pmid">21869824</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witzens-Harig</surname><given-names>M</given-names></name><name><surname>Hose</surname><given-names>D</given-names></name><name><surname>Junger</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>4493</fpage><lpage>4503</lpage><comment>doi:10.1182/blood-2012-05-429415</comment><pub-id pub-id-type="pmid">23603913</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muturi</surname><given-names>HT</given-names></name><name><surname>Dreesen</surname><given-names>JD</given-names></name><name><surname>Nilewski</surname><given-names>E</given-names></name><name><surname>Jastrow</surname><given-names>H</given-names></name><name><surname>Giebel</surname><given-names>B</given-names></name><name><surname>Ergun</surname><given-names>S</given-names></name><name><surname>Singer</surname><given-names>BB</given-names></name></person-group><article-title>Tumor and endothelial cell-derived microvesicles carry distinct CEACAMs and influence T-cell behavior</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e74654</fpage><comment>doi:10.1371/journal.pone.0074654</comment><pub-id pub-id-type="pmid">24040308</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>MM</given-names></name><name><surname>Singer</surname><given-names>BB</given-names></name><name><surname>Klaile</surname><given-names>E</given-names></name><name><surname>Obrink</surname><given-names>B</given-names></name><name><surname>Lucka</surname><given-names>L</given-names></name></person-group><article-title>Transmembrane CEACAM1 affects integrin-dependent signaling and regulates extracellular matrix protein-specific morphology and migration of endothelial cells</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>3925</fpage><lpage>3934</lpage><comment>doi:10.1182/blood-2004-09-3618</comment><pub-id pub-id-type="pmid">15687237</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vannucci</surname><given-names>L</given-names></name></person-group><article-title>Stroma as an active player in the development of the tumor microenvironment</article-title><source>Cancer Microenviron</source><year>2014</year><comment>doi:10.1007/s12307-014-0150-x</comment></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weichselbaumer</surname><given-names>M</given-names></name><name><surname>Willmann</surname><given-names>M</given-names></name><name><surname>Reifinger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phylogenetic discordance of human and canine carcinoembryonic antigen (CEA, CEACAM) families, but striking identity of the CEA receptors will impact comparative oncology studies</article-title><source>PLoS Curr</source><year>2011</year><volume>3</volume><fpage>RRN1223</fpage><comment>doi:10.1371/currents.RRN1223</comment><pub-id pub-id-type="pmid">21436956</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajenova</surname><given-names>OV</given-names></name><name><surname>Zimmer</surname><given-names>R</given-names></name><name><surname>Stolper</surname><given-names>E</given-names></name><name><surname>Salisbury-Rowswell</surname><given-names>J</given-names></name><name><surname>Nanji</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name></person-group><article-title>Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>31067</fpage><lpage>31073</lpage><comment>doi:10.1074/jbc.M104093200</comment><pub-id pub-id-type="pmid">11406629</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laguinge</surname><given-names>L</given-names></name><name><surname>Bajenova</surname><given-names>O</given-names></name><name><surname>Bowden</surname><given-names>E</given-names></name><name><surname>Sayyah</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Juhl</surname><given-names>H</given-names></name></person-group><article-title>Surface expression and CEA binding of hnRNP M4 protein in HT29 colon cancer cells</article-title><source>Anticancer Res</source><year>2005</year><volume>25</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15816515</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>HM</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name></person-group><article-title>Expression of carcinoembryonic antigen receptor in digestive organs</article-title><source>Zhonghua Wei Chang Wai Ke Za Zhi</source><year>2010</year><volume>13</volume><fpage>608</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">20737316</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Forse</surname><given-names>RA</given-names></name><name><surname>Bajenova</surname><given-names>O</given-names></name></person-group><article-title>Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver</article-title><source>Clin Exp Metastasis</source><year>2011</year><volume>28</volume><fpage>923</fpage><lpage>932</lpage><comment>doi:10.1007/s10585-011-9419-3</comment><pub-id pub-id-type="pmid">21901530</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palermo</surname><given-names>NY</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Murphy</surname><given-names>RF</given-names></name><name><surname>Lovas</surname><given-names>S</given-names></name></person-group><article-title>Hexapeptide fragment of carcinoembryonic antigen which acts as an agonist of heterogeneous ribonucleoprotein M</article-title><source>J Pept Sci</source><year>2012</year><volume>18</volume><fpage>252</fpage><lpage>260</lpage><comment>doi:10.1002/psc.2393</comment><pub-id pub-id-type="pmid">22392880</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Jiao</surname><given-names>Z</given-names></name><name><surname>Pakala</surname><given-names>SB</given-names></name><name><surname>Sirigiri</surname><given-names>DN</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Mishra</surname><given-names>L</given-names></name></person-group><article-title>Carcinoembryonic antigen interacts with TGF-{beta} receptor and inhibits TGF-{beta} signaling in colorectal cancers</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>8159</fpage><lpage>8168</lpage><comment>doi:10.1158/0008-5472.CAN-10-1073</comment><pub-id pub-id-type="pmid">20889724</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>PJ</given-names></name><name><surname>Deep</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>AB</given-names></name><name><surname>Shu</surname><given-names>Z</given-names></name><name><surname>Hinck</surname><given-names>CS</given-names></name><name><surname>Hinck</surname><given-names>AP</given-names></name></person-group><article-title>Crystal structure of the human TbetaR2 ectodomain-TGF-beta3 complex</article-title><source>Nat Struct Biol</source><year>2002</year><volume>9</volume><fpage>203</fpage><lpage>208</lpage><comment>doi:10.1038/nsb766</comment><pub-id pub-id-type="pmid">11850637</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrana</surname><given-names>JL</given-names></name><name><surname>Attisano</surname><given-names>L</given-names></name><name><surname>Carcamo</surname><given-names>J</given-names></name><name><surname>Zentella</surname><given-names>A</given-names></name><name><surname>Doody</surname><given-names>J</given-names></name><name><surname>Laiho</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>XF</given-names></name><name><surname>Massague</surname><given-names>J</given-names></name></person-group><article-title>TGF beta signals through a heteromeric protein kinase receptor complex</article-title><source>Cell</source><year>1992</year><volume>71</volume><fpage>1003</fpage><lpage>1014</lpage><comment>doi:10.1016/0092-8674(92)90395-S</comment><pub-id pub-id-type="pmid">1333888</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>David</surname><given-names>L</given-names></name><name><surname>Mendoza</surname><given-names>V</given-names></name><etal/></person-group><article-title>TGF-&#x003b2; signalling is mediated by two autonomously functioning T&#x003b2;RI: T&#x003b2;RII pairs</article-title><source>EMBO J</source><year>2011</year><volume>30</volume><fpage>1263</fpage><lpage>1276</lpage><comment>doi:10.1038/emboj.2011.54</comment><pub-id pub-id-type="pmid">21423151</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adeegbe</surname><given-names>DO</given-names></name><name><surname>Nishikawa</surname><given-names>H</given-names></name></person-group><article-title>Natural and induced T regulatory cells in cancer</article-title><source>Front Immunol</source><year>2013</year><volume>4</volume><fpage>190</fpage><comment>doi:10.3389/fimmu.2013.00190</comment><pub-id pub-id-type="pmid">23874336</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>MI</given-names></name><name><surname>Pires</surname><given-names>I</given-names></name><name><surname>Prada</surname><given-names>J</given-names></name><name><surname>Queiroga</surname><given-names>FL</given-names></name></person-group><article-title>A role for T-lymphocytes in human breast cancer and in canine mammary tumors</article-title><source>Biomed Res Int</source><year>2014</year><volume>2014</volume><fpage>130894</fpage><comment>doi:10.1155/2014/130894</comment><pub-id pub-id-type="pmid">24672781</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>K</given-names></name><name><surname>Guth</surname><given-names>A</given-names></name><name><surname>Biller</surname><given-names>B</given-names></name><name><surname>Elmslie</surname><given-names>R</given-names></name><name><surname>Dow</surname><given-names>S</given-names></name></person-group><article-title>Changes in regulatory T cells in dogs with cancer and associations with tumor type</article-title><source>J Vet Intern Med</source><year>2009</year><volume>23</volume><fpage>875</fpage><lpage>881</lpage><comment>doi:10.1111/j.1939-1676.2009.0333.x</comment><pub-id pub-id-type="pmid">19496904</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinheiro</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>YM</given-names></name><name><surname>Bryant</surname><given-names>H</given-names></name><etal/></person-group><article-title>Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3 + T cells in canine B cell lymphoma</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e105027</fpage><comment>doi:10.1371/journal.pone.0105027</comment><pub-id pub-id-type="pmid">25119018</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteside</surname><given-names>TL</given-names></name></person-group><article-title>Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?</article-title><source>Cancer Immunol Immunother: CII</source><year>2014</year><volume>63</volume><fpage>67</fpage><lpage>72</lpage><comment>doi:10.1007/s00262-013-1490-y</comment></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biragyn</surname><given-names>A</given-names></name><name><surname>Lee-Chang</surname><given-names>C</given-names></name><name><surname>Bodogai</surname><given-names>M</given-names></name></person-group><article-title>Generation and identification of tumor-evoked regulatory B cells</article-title><source>Methods Mol Biol</source><year>2014</year><volume>1190</volume><fpage>271</fpage><lpage>289</lpage><comment>doi:10.1007/978-1-4939-1161-5_19</comment><pub-id pub-id-type="pmid">25015287</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindner</surname><given-names>S</given-names></name><name><surname>Dahlke</surname><given-names>K</given-names></name><name><surname>Sontheimer</surname><given-names>K</given-names></name><etal/></person-group><article-title>Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells</article-title><source>Cancer Res</source><year>2013</year><volume>73</volume><fpage>2468</fpage><lpage>2479</lpage><comment>doi:10.1158/0008-5472.CAN-12-3450</comment><pub-id pub-id-type="pmid">23384943</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olkhanud</surname><given-names>PB</given-names></name><name><surname>Damdinsuren</surname><given-names>B</given-names></name><name><surname>Bodogai</surname><given-names>M</given-names></name><name><surname>Gress</surname><given-names>RE</given-names></name><name><surname>Sen</surname><given-names>R</given-names></name><name><surname>Wejksza</surname><given-names>K</given-names></name><name><surname>Malchinkhuu</surname><given-names>E</given-names></name><name><surname>Wersto</surname><given-names>RP</given-names></name><name><surname>Biragyn</surname><given-names>A</given-names></name></person-group><article-title>Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>3505</fpage><lpage>3515</lpage><comment>doi:10.1158/0008-5472.CAN-10-4316</comment><pub-id pub-id-type="pmid">21444674</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mele</surname><given-names>V</given-names></name><name><surname>Muraro</surname><given-names>MG</given-names></name><name><surname>Calabrese</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF-beta</article-title><source>Int J Cancer</source><year>2014</year><volume>134</volume><fpage>2583</fpage><lpage>2594</lpage><comment>doi:10.1002/ijc.28598</comment><pub-id pub-id-type="pmid">24214914</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Rahmatpanah</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zi</surname><given-names>X</given-names></name><name><surname>McClelland</surname><given-names>M</given-names></name><name><surname>Mercola</surname><given-names>D</given-names></name></person-group><article-title>Role of the adjacent stroma cells in prostate cancer development and progression: synergy between TGF-beta and IGF signaling</article-title><source>Biomed Res Int</source><year>2014</year><volume>2014</volume><fpage>502093</fpage><comment>doi:10.1155/2014/502093</comment><pub-id pub-id-type="pmid">25089270</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Jing</surname><given-names>S</given-names></name></person-group><article-title>Notch and TGF-beta/Smad3 pathways are involved in the interaction between cancer cells and cancer-associated fibroblasts in papillary thyroid carcinoma</article-title><source>Tumour Biol</source><year>2014</year><volume>35</volume><fpage>379</fpage><lpage>385</lpage><comment>doi:10.1007/s13277-013-1053-z</comment><pub-id pub-id-type="pmid">23918305</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>DK</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Sahu</surname><given-names>DK</given-names></name></person-group><article-title>TGF-beta mediated crosstalk between malignant hepatocyte and tumor microenvironment in hepatocellular carcinoma</article-title><source>Cancer Growth Metastasis</source><year>2014</year><volume>7</volume><fpage>1</fpage><lpage>8</lpage><comment>doi:10.4137/CGM.S14205</comment><pub-id pub-id-type="pmid">24741325</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cufi</surname><given-names>S</given-names></name><name><surname>Vazquez-Martin</surname><given-names>A</given-names></name><name><surname>Oliveras-Ferraros</surname><given-names>C</given-names></name><name><surname>Martin-Castillo</surname><given-names>B</given-names></name><name><surname>Joven</surname><given-names>J</given-names></name><name><surname>Menendez</surname><given-names>JA</given-names></name></person-group><article-title>Metformin against TGF-beta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis</article-title><source>Cell Cycle</source><year>2010</year><volume>9</volume><fpage>4461</fpage><lpage>4468</lpage><pub-id pub-id-type="pmid">21088486</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunning</surname><given-names>NL</given-names></name><name><surname>Laversin</surname><given-names>SA</given-names></name><name><surname>Miles</surname><given-names>AK</given-names></name><name><surname>Rees</surname><given-names>RC</given-names></name></person-group><article-title>Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?</article-title><source>Cancer Immunol Immunother: CII</source><year>2011</year><volume>60</volume><fpage>1181</fpage><lpage>1193</lpage><comment>doi:10.1007/s00262-011-1065-8</comment></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name></person-group><article-title>EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>4741</fpage><lpage>4751</lpage><comment>doi:10.1038/onc.2010.215</comment><pub-id pub-id-type="pmid">20531305</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>MA</given-names></name><name><surname>Sossey-Alaoui</surname><given-names>K</given-names></name><name><surname>Thompson</surname><given-names>CL</given-names></name><name><surname>Danielpour</surname><given-names>D</given-names></name><name><surname>Schiemann</surname><given-names>WP</given-names></name></person-group><article-title>TGF-beta upregulates miR-181a expression to promote breast cancer metastasis</article-title><source>J Clin Investig</source><year>2013</year><volume>123</volume><fpage>150</fpage><lpage>163</lpage><comment>doi:10.1172/JCI64946</comment><pub-id pub-id-type="pmid">23241956</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Hur</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Im</surname><given-names>KS</given-names></name><name><surname>Kim</surname><given-names>NH</given-names></name><name><surname>Sur</surname><given-names>JH</given-names></name></person-group><article-title>Correlation of Foxp3 positive regulatory T cells with prognostic factors in canine mammary carcinomas</article-title><source>Vet J</source><year>2012</year><volume>193</volume><fpage>222</fpage><lpage>227</lpage><comment>doi:10.1016/j.tvjl.2011.10.022</comment><pub-id pub-id-type="pmid">22130461</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moo-Young</surname><given-names>TA</given-names></name><name><surname>Larson</surname><given-names>JW</given-names></name><name><surname>Belt</surname><given-names>BA</given-names></name><name><surname>Tan</surname><given-names>MC</given-names></name><name><surname>Hawkins</surname><given-names>WG</given-names></name><name><surname>Eberlein</surname><given-names>TJ</given-names></name><name><surname>Goedegebuure</surname><given-names>PS</given-names></name><name><surname>Linehan</surname><given-names>DC</given-names></name></person-group><article-title>Tumor-derived TGF-beta mediates conversion of CD4 + Foxp3 + regulatory T cells in a murine model of pancreas cancer</article-title><source>J Immunother</source><year>2009</year><volume>32</volume><fpage>12</fpage><lpage>21</lpage><comment>doi:10.1097/CJI.0b013e318189f13c</comment><pub-id pub-id-type="pmid">19307989</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters</article-title><source>Oncol Rep</source><year>2013</year><volume>30</volume><issue>3</issue><fpage>1215</fpage><lpage>1222</lpage><comment>doi:10.3892/or.2013.2570</comment><pub-id pub-id-type="pmid">23807713</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kammerer</surname><given-names>R</given-names></name><name><surname>von Kleist</surname><given-names>S</given-names></name></person-group><article-title>The carcinoembryonic antigen (CEA) modulates effector-target cell interaction by binding to activated lymphocytes</article-title><source>Int J Cancer</source><year>1996</year><volume>68</volume><fpage>457</fpage><lpage>463</lpage><comment>doi:10.1002/(SICI)1097-0215(19961115)68:4&#x0003c;457:AID-IJC10&#x0003e;3.0.CO;2-2</comment><pub-id pub-id-type="pmid">8945616</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Baker</surname><given-names>K</given-names></name><etal/></person-group><article-title>The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction</article-title><source>Immunity</source><year>2012</year><volume>37</volume><fpage>930</fpage><lpage>946</lpage><comment>doi:10.1016/j.immuni.2012.07.016</comment><pub-id pub-id-type="pmid">23123061</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oeckinghaus</surname><given-names>A</given-names></name><name><surname>Hayden</surname><given-names>MS</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><article-title>Crosstalk in NF-kappaB signaling pathways</article-title><source>Nat Immunol</source><year>2011</year><volume>12</volume><fpage>695</fpage><lpage>708</lpage><comment>doi:10.1038/ni.2065</comment><pub-id pub-id-type="pmid">21772278</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Luedde</surname><given-names>T</given-names></name><name><surname>Schmidt-Supprian</surname><given-names>M</given-names></name></person-group><article-title>Dissection of the NF-kappaB signalling cascade in transgenic and knockout mice</article-title><source>Cell Death Differ</source><year>2006</year><volume>13</volume><fpage>861</fpage><lpage>872</lpage><comment>doi:10.1038/sj.cdd.4401870</comment><pub-id pub-id-type="pmid">16470223</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freudlsperger</surname><given-names>C</given-names></name><name><surname>Bian</surname><given-names>Y</given-names></name><name><surname>Contag Wise</surname><given-names>S</given-names></name><name><surname>Burnett</surname><given-names>J</given-names></name><name><surname>Coupar</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Van Waes</surname><given-names>C</given-names></name></person-group><article-title>TGF-beta and NF-kappaB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>1549</fpage><lpage>1559</lpage><comment>doi:10.1038/onc.2012.171</comment><pub-id pub-id-type="pmid">22641218</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>SU</given-names></name><name><surname>Kwak</surname><given-names>TH</given-names></name><name><surname>Her</surname><given-names>KH</given-names></name><etal/></person-group><article-title>CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>675</fpage><lpage>683</lpage><comment>doi:10.1038/sj.onc.1210686</comment><pub-id pub-id-type="pmid">17653079</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gingery</surname><given-names>A</given-names></name><name><surname>Bradley</surname><given-names>EW</given-names></name><name><surname>Pederson</surname><given-names>L</given-names></name><name><surname>Ruan</surname><given-names>M</given-names></name><name><surname>Horwood</surname><given-names>NJ</given-names></name><name><surname>Oursler</surname><given-names>MJ</given-names></name></person-group><article-title>TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival</article-title><source>Exp Cell Res</source><year>2008</year><volume>314</volume><fpage>2725</fpage><lpage>2738</lpage><comment>doi:10.1016/j.yexcr.2008.06.006</comment><pub-id pub-id-type="pmid">18586026</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>RL</given-names></name><name><surname>Blobe</surname><given-names>GC</given-names></name></person-group><article-title>Role of transforming growth factor Beta in human cancer</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>2078</fpage><lpage>2093</lpage><comment>doi:10.1200/JCO.2005.02.047</comment><pub-id pub-id-type="pmid">15774796</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calon</surname><given-names>A</given-names></name><name><surname>Espinet</surname><given-names>E</given-names></name><name><surname>Palomo-Ponce</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation</article-title><source>Cancer Cell</source><year>2012</year><volume>22</volume><fpage>571</fpage><lpage>584</lpage><comment>doi:10.1016/j.ccr.2012.08.013</comment><pub-id pub-id-type="pmid">23153532</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naugler</surname><given-names>WE</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>NF-kappaB and cancer-identifying targets and mechanisms</article-title><source>Curr Opin Genet Dev</source><year>2008</year><volume>18</volume><fpage>19</fpage><lpage>26</lpage><comment>doi:10.1016/j.gde.2008.01.020</comment><pub-id pub-id-type="pmid">18440219</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ear</surname><given-names>T</given-names></name><name><surname>Fortin</surname><given-names>CF</given-names></name><name><surname>Simard</surname><given-names>FA</given-names></name><name><surname>McDonald</surname><given-names>PP</given-names></name></person-group><article-title>Constitutive association of TGF-beta-activated kinase 1 with the IkappaB kinase complex in the nucleus and cytoplasm of human neutrophils and its impact on downstream processes</article-title><source>J Immunol</source><year>2010</year><volume>184</volume><fpage>3897</fpage><lpage>3906</lpage><comment>doi:10.4049/jimmunol.0902958</comment><pub-id pub-id-type="pmid">20200282</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neil</surname><given-names>JR</given-names></name><name><surname>Schiemann</surname><given-names>WP</given-names></name></person-group><article-title>Altered TAB 1: I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>1462</fpage><lpage>1470</lpage><comment>doi:10.1158/0008-5472.CAN-07-3094</comment><pub-id pub-id-type="pmid">18316610</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oida</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>A</given-names></name><name><surname>Jung</surname><given-names>K</given-names></name><etal/></person-group><article-title>Nuclear factor-kB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells</article-title><source>Sci Rep</source><year>2014</year><volume>4</volume><fpage>4057</fpage><comment>doi:10.1038/srep04057</comment><pub-id pub-id-type="pmid">24531845</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindblad-Toh</surname><given-names>K</given-names></name><name><surname>Wade</surname><given-names>CM</given-names></name><name><surname>Mikkelsen</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Genome sequence, comparative analysis and haplotype structure of the domestic dog</article-title><source>Nature</source><year>2005</year><volume>438</volume><fpage>803</fpage><lpage>819</lpage><comment>doi:10.1038/nature04338</comment><pub-id pub-id-type="pmid">16341006</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>S</given-names></name><name><surname>Willenbrock</surname><given-names>S</given-names></name><name><surname>Nolte</surname><given-names>I</given-names></name><name><surname>Murua Escobar</surname><given-names>H</given-names></name></person-group><article-title>Comparison of non-coding RNAs in human and canine cancer</article-title><source>Front Genet</source><year>2013</year><volume>4</volume><fpage>46</fpage><comment>doi:10.3389/fgene.2013.00046</comment><pub-id pub-id-type="pmid">23579348</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riccardo</surname><given-names>F</given-names></name><name><surname>Aurisicchio</surname><given-names>L</given-names></name><name><surname>Impellizeri</surname><given-names>JA</given-names></name><name><surname>Cavallo</surname><given-names>F</given-names></name></person-group><article-title>The importance of comparative oncology in translational medicine</article-title><source>Cancer Immunol Immunother: CII</source><year>2015</year><volume>64</volume><fpage>137</fpage><lpage>148</lpage><comment>doi:10.1007/s00262-014-1645-5</comment></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Interconnected networks of CEA and TGF-&#x003b2; signaling in cancer. The cancer cell is an autocrine source of CEA as well as of TGF-&#x003b2; which bind to their specific receptors, CEAR or TGF-&#x003b2;-RI:RII, respectively; the latter signaling via the NF&#x003ba;B pathway. Recently, it has been recognized that CEA also signals via TGF-&#x003b2;-R and initiates the same biological effects [<xref rid="R26" ref-type="bibr">26</xref>]. Additionally, Tregs and Bregs, as well as stroma cells, participate in this network by secreting TGF-&#x003b2;. It remains open whether the reverse is the case, and TGF-&#x003b2; may also interfere with the CEAR pathway, which is much less defined</p></caption><graphic xlink:href="emss-63119-f0001"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Interspecies amino acid sequence comparisons</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Molecule</th><th align="left" valign="middle" rowspan="1" colspan="1">Human</th><th align="left" valign="middle" rowspan="1" colspan="1">Canine</th><th align="left" valign="middle" rowspan="1" colspan="1">Sequence identity (%)</th><th align="left" valign="middle" rowspan="1" colspan="1">Sequence similarity (%)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">CEAR</td><td align="left" valign="middle" rowspan="1" colspan="1">HNRPM_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">XP_005633012.1</td><td align="left" valign="middle" rowspan="1" colspan="1">99.3</td><td align="left" valign="middle" rowspan="1" colspan="1">99.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CEA (CEACAM5)</td><td align="left" valign="middle" rowspan="1" colspan="1">CEAM5_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">n.d. [<xref rid="R20" ref-type="bibr">20</xref>]</td><td align="left" valign="middle" rowspan="1" colspan="1">
&#x02013;
</td><td align="left" valign="middle" rowspan="1" colspan="1">
&#x02013;
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-&#x003b2;-RI</td><td align="left" valign="middle" rowspan="1" colspan="1">TGFR1_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">F1PS63_CANFA</td><td align="left" valign="middle" rowspan="1" colspan="1">91.8</td><td align="left" valign="middle" rowspan="1" colspan="1">92.2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-&#x003b2;-RII</td><td align="left" valign="middle" rowspan="1" colspan="1">TGFR2_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">F1PNA9_CANFA</td><td align="left" valign="middle" rowspan="1" colspan="1">87.4</td><td align="left" valign="middle" rowspan="1" colspan="1">90.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-&#x003b2;-RIII</td><td align="left" valign="middle" rowspan="1" colspan="1">TGBR3_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">F1PIG0_CANFA</td><td align="left" valign="middle" rowspan="1" colspan="1">88.6</td><td align="left" valign="middle" rowspan="1" colspan="1">93.0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-&#x003b2;1</td><td align="left" valign="middle" rowspan="1" colspan="1">TGFB1_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">TGFB1-CANFA</td><td align="left" valign="middle" rowspan="1" colspan="1">94.1</td><td align="left" valign="middle" rowspan="1" colspan="1">96.7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-&#x003b2;2</td><td align="left" valign="middle" rowspan="1" colspan="1">TGFB2_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">F1PKH0_CANFA</td><td align="left" valign="middle" rowspan="1" colspan="1">99.5</td><td align="left" valign="middle" rowspan="1" colspan="1">99.8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-&#x003b2;3</td><td align="left" valign="middle" rowspan="1" colspan="1">TGFB3_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">F1PR85_CANFA</td><td align="left" valign="middle" rowspan="1" colspan="1">88.4</td><td align="left" valign="middle" rowspan="1" colspan="1">89.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NF&#x003ba;B1</td><td align="left" valign="middle" rowspan="1" colspan="1">NF&#x003ba;B1_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">NF&#x003ba;B1_CANFA</td><td align="left" valign="middle" rowspan="1" colspan="1">91.0</td><td align="left" valign="middle" rowspan="1" colspan="1">94.2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NF&#x003ba;B2</td><td align="left" valign="middle" rowspan="1" colspan="1">NF&#x003ba;B2_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">E2RLL2_CANFA</td><td align="left" valign="middle" rowspan="1" colspan="1">92.3</td><td align="left" valign="middle" rowspan="1" colspan="1">94.9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RelA</td><td align="left" valign="middle" rowspan="1" colspan="1">TF65_HUMAN</td><td align="left" valign="middle" rowspan="1" colspan="1">F1PCU1_CANFA</td><td align="left" valign="middle" rowspan="1" colspan="1">91.2</td><td align="left" valign="middle" rowspan="1" colspan="1">93.5</td></tr></tbody></table><table-wrap-foot><p>Sequences were from UniProt (<ext-link ext-link-type="uri" xlink:href="http://www.uniprot.org/uniprot/">http://www.uniprot.org/uniprot/</ext-link>) and from the National Center for Biotechnology Information (NCBI) (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein">http://www.ncbi.nlm.nih.gov/protein</ext-link>). Sequences were aligned using a Needleman&#x02013;Wunsch algorithm (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/Tools/psa/">http://www.ebi.ac.uk/Tools/psa/</ext-link>) with a BLOSUM 62 matrix; gap penalty and end penalty were defined as 10.0 and 0.5, respectively</p></table-wrap-foot></table-wrap></floats-group></article>